{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Windlas Biotech Faces Bearish Technical Trends Amidst Market Challenges
Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly.
Windlas Biotech Forms Death Cross, Signaling Potential Bearish Trend Ahead
Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average.
Why is Windlas Biotech falling/rising?
As of 07-Nov, Windlas Biotech Ltd's stock price is Rs 867.80, down 6.08% after three consecutive days of decline. Despite strong quarterly results, the stock's long-term growth concerns and underperformance against the market have led to a negative year-to-date return of 16.03%.
Are Windlas Biotech latest results good or bad?
Windlas Biotech's latest results show strong revenue growth, with Q2 FY26 revenue at ₹222.40 crores, but profitability is a concern as margins have compressed and costs have risen significantly. While the company has a strong balance sheet, it faces challenges in translating revenue growth into improved profits.
Windlas Biotech Hits Day Low at Rs 863.2 Amid Price Pressure
Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%.
Windlas Biotech Faces Technical Shift Amidst Mixed Financial Performance Indicators
Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year.
Windlas Biotech Faces Mixed Technical Trends Amidst Market Challenges
Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period.
How has been the historical performance of Windlas Biotech?
Windlas Biotech has shown consistent growth from March 2020 to March 2025, with net sales increasing from 328.85 Cr to 759.88 Cr and profit after tax rising from 16.21 Cr to 60.99 Cr, reflecting strong profitability and asset expansion. Total assets grew from 337.82 Cr to 760.17 Cr, indicating robust financial performance.
Windlas Biotech Q2 FY26: Strong Revenue Growth Masks Margin Pressures and Valuation Concerns
Windlas Biotech Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported a net profit of ₹17.80 crores for Q2 FY26, marking a modest sequential increase of 0.79% from ₹17.66 crores in Q1 FY26. On a year-on-year basis, net profit grew 13.67% from ₹15.66 crores in Q2 FY25. With a market capitalisation of ₹1,973 crores and a current price of ₹932.90, the stock has declined 17.01% over the past year, significantly underperforming both the Sensex and its pharmaceutical sector peers.
Is Windlas Biotech technically bullish or bearish?
As of November 4, 2025, the technical trend is neutral with mixed indicators, showing a shift from mildly bullish to sideways, as the weekly MACD is bearish, the monthly MACD is mildly bearish, and other indicators reflect conflicting signals.
Windlas Biotech Experiences Mixed Technical Trends Amid Market Evaluation Revision
Windlas Biotech, a small-cap pharmaceutical company, has seen its stock price decline recently, with mixed technical indicators reflecting its market performance. While it has outperformed the Sensex over the past week, longer-term returns show declines year-to-date and over the past year, despite significant growth over three years.
Is Windlas Biotech technically bullish or bearish?
As of November 4, 2025, the market trend is sideways with mixed signals, showing bearish tendencies in longer time frames despite some mildly bullish indicators on daily charts.
Why is Windlas Biotech falling/rising?
As of 24-Sep, Windlas Biotech Ltd is priced at 931.00, down 1.09% and underperforming with a 3.31% decline over the last three days. The stock is trading below key moving averages and has seen a significant drop in delivery volume, indicating bearish sentiment and reduced investor participation.
Why is Windlas Biotech falling/rising?
As of 23-Sep, Windlas Biotech Ltd is priced at 950.00, having increased by 0.64% today but declined 4.90% over the past week. Despite short-term bearish trends, the stock has a strong long-term outlook with a 9.95% return over the past year and significant growth over the last three years.
Why is Windlas Biotech falling/rising?
As of 22-Sep, Windlas Biotech Ltd's stock price is Rs 945.30, down 1.82%, and has underperformed its sector. The stock is in a bearish trend, trading below key moving averages, with a recent decline in investor participation and a high PEG ratio indicating potential overvaluation.
Why is Windlas Biotech falling/rising?
As of 19-Sep, Windlas Biotech Ltd's stock is priced at 962.50, showing a slight increase after a trend reversal following three days of decline. Despite recent declines over the week and month, the company reports strong financials and a low debt-to-equity ratio, indicating potential stability and investor interest.
Is Windlas Biotech technically bullish or bearish?
As of September 18, 2025, Windlas Biotech's technical trend is mildly bullish, supported by the weekly MACD, KST, and OBV indicators, despite mixed signals from the monthly MACD and caution suggested by the RSI.
Windlas Biotech Shows Mixed Technical Trends Amid Market Evaluation Revision
Windlas Biotech, a small-cap pharmaceutical company, has experienced a recent stock price decline amid mixed technical indicators. Despite short-term challenges, the company has demonstrated resilience with significant long-term returns, outperforming the Sensex over three years, showcasing its capacity to adapt to market changes.
Why is Windlas Biotech falling/rising?
As of 18-Sep, Windlas Biotech Ltd is priced at Rs 961.50, down 1.31% and has underperformed its sector and the benchmark Sensex recently. Despite a positive annual return of 10.00%, the stock's recent decline and high PEG ratio suggest potential overvaluation and challenges in maintaining investor confidence.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
